EdiGene | Genome Editing for a Better Life

Genome Editing for a Better Life

Four Genome Editing Based Platforms

Our Pipeline
Ex vivo and in vivo gene-editing therapies,
and targeted therapies

Patient focused

Genetic diseases

Cancer

News

Press Releases

EdiGene Announces Approval of its IND Application for its CRISPR/Cas 9 Gene-edit ...

Read More》

Press Releases

EdiGene Expands Management Team by Appointment of Head of US Subsidiary Dr. Bo Zhang and Head of Business Development Dr. Kehua Fan

Read More》
Press Releases

EdiGene Announces IND Application for its CRISPR/Cas 9 Gene-editing Hematopoietic Stem Cell Therapy ET-01 in β-thalassemia Accepted for Review by China National Medical Products Administration

Read More》
Press Releases

EdiGene Raises Approximately USD 67 Million in Series B Financing to Advance Gene Editing Based Programs into Clinical Stage

Read More》
In the Media

Application given for gene therapy trials to treat blood disease

CHINADAILY
Read More》

Follow us on WeChat

Contact Us

Careers : hr@EdiGene.com
Partnership : bd@EdiGene.com
Media Inquiries : media@EdiGene.com

About Us

Company Overview Scientific Founder Leadership Contact Us

Our Business

Gene Editing Our Pipeline Our Focus

News

Press Releases In the Media

Careers

Join Us

Copyright © 2020 EdiGene Inc. All Rights Reserved.